Pasireotide with or without cabergoline
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushings Disease
Conditions
Cushings Disease
Trial Timeline
Mar 6, 2014 → Sep 4, 2019
NCT ID
NCT01915303About Pasireotide with or without cabergoline
Pasireotide with or without cabergoline is a phase 2 stage product being developed by Novartis for Cushings Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01915303. Target conditions include Cushings Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01915303 | Phase 2 | Terminated |
Competing Products
3 competing products in Cushings Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| LCI699 | Novartis | Phase 2 | 52 |
| Pasireotide | Recordati | Pre-clinical | 20 |